Chronic Carditis: Causes, Symptoms, and Treatment

Chronic carditis is persistent inflammation of one or more layers of the heart that lasts weeks to months or smolders for years, gradually replacing healthy muscle with scar tissue and stiffening the organ in ways that impair its ability to pump and fill. The term “carditis” itself is descriptive rather than a single diagnosis: it can refer to inflammation of the pericardium (the sac surrounding the heart), the myocardium (the muscle), the endocardium (the inner lining and valves), or all three at once.¹ What makes it chronic is that the inflammatory process does not resolve on its own after the initial insult, instead cycling through flares or quietly progressing until the structural damage becomes clinically apparent.

Why Heart Inflammation Becomes Chronic

Acute carditis is common enough. A viral chest cold can transiently inflame the heart muscle, and many cases resolve without anyone knowing they happened. Chronic carditis develops when the immune response that was supposed to clear the original trigger instead persists, either because the pathogen is never fully eliminated, because the immune system begins attacking the heart’s own proteins, or because ongoing exposure to a toxin keeps reigniting inflammation. Several broad categories of causes feed into this process.

Post-Streptococcal and Rheumatic Heart Disease

Rheumatic heart disease remains the most common cause of chronic carditis worldwide, particularly in low- and middle-income countries. It begins with a group A streptococcal throat infection, but the damage is not done by the bacterium itself. Instead, the immune system’s antibodies against the streptococcal surface also bind to proteins on the heart valve lining, a phenomenon researchers call molecular mimicry. Human antibodies from rheumatic heart disease patients cross-react with a dominant streptococcal sugar and with heart valve endothelium, laminin, and the basement membrane beneath it.² T cells that recognize streptococcal M protein also recognize cardiac myosin, and once these cells infiltrate the valve, they form the characteristic granulomatous lesions known as Aschoff bodies. The process involves a “two-hit” sequence: antibodies first damage the valve surface, then T cells pass through the activated endothelium and set up camp inside the valve tissue.²

Research has extended this mimicry model further, showing that the streptococcal bacterium mimics not just myosin but also laminin, collagen IV, and the coxsackievirus-adenovirus receptor (CAR). One hypothesis suggests that combined infections of group A streptococcus with coxsackievirus at the level of heart muscle cells may produce a synergistic inflammatory response that cross-reacts with multiple structural proteins in and around the heart.³ Over time, the immune attack causes progressive scarring and thickening of the valves, particularly the mitral valve, leading to regurgitation or stenosis that worsens with each recurrence of streptococcal infection.

Viral Persistence and Chronic Myocarditis

Several viruses can infect the myocardium, including enteroviruses, adenoviruses, parvovirus B19, and human herpesvirus 6. In many people, the immune system clears the virus completely and the heart recovers. But in a substantial number it does not. A study that followed patients with viral myocarditis using serial heart biopsies found that viral genomes were spontaneously cleared in only about a third of cases with single infections. Parvovirus B19 was especially stubborn, clearing in roughly one in five patients. When patients had dual infections with parvovirus B19 and human herpesvirus 6, parvovirus persisted in every single case.⁴

The clinical consequences were clear: patients who cleared the virus saw their heart pumping function improve significantly, while those with persistent virus experienced a gradual decline.⁴ This is the essence of chronic viral myocarditis. The virus lingers, the immune response grinds on, and the heart muscle slowly loses ground.

Chagas Disease

In Latin America, the parasite Trypanosoma cruzi causes Chagas disease, whose most severe long-term complication is chronic chagasic cardiomyopathy. The parasite survives inside host cells for years by manipulating the cell’s own death machinery: it blocks programmed cell death in the cells it occupies while inducing death in the immune cells trying to kill it.⁵ This persistent low-grade infection drives decades of inflammation, fibrosis, and progressive heart failure, making Chagas a leading cause of heart-related death in endemic regions.

Culture-Negative Endocarditis

Some bacterial causes of chronic endocarditis are easy to miss because the organisms do not grow in standard blood cultures. In a study of community-acquired, culture-negative endocarditis in Brazil, about one in five cases was caused by Bartonella species and about one in twelve by Coxiella burnetii, the agent of Q fever.⁶ Bartonella henselae was especially prevalent among cat owners. Because these infections do not announce themselves through positive blood cultures, they can simmer for months before the valve damage becomes severe enough to prompt further testing.

Autoimmune and Systemic Causes

Chronic carditis does not always trace back to an infection. Systemic autoimmune diseases frequently involve the heart, sometimes as a defining feature and sometimes as a complication that develops silently over years.

Systemic lupus erythematosus (SLE) is a well-known offender. Libman-Sacks endocarditis, a form of sterile valve inflammation, was found in about one in nine lupus patients in a large echocardiographic survey. The mitral valve was involved most often, producing regurgitation in every affected patient and co-existing stenosis in a subset. Libman-Sacks endocarditis was significantly associated with disease duration, disease activity, blood clots, stroke, and the presence of antiphospholipid antibodies.⁷ The inflammation can progress from the subendocardial layer through thrombosis to fibrosis, sometimes appearing in unusual locations such as the left ventricular wall rather than on the valves.⁸

Cancer immunotherapy has introduced a newer form of autoimmune carditis. Immune checkpoint inhibitors, which work by releasing the brakes on the immune system to attack tumors, can occasionally unleash that same immune aggression against the heart. Though uncommon, checkpoint inhibitor myocarditis can be fulminant and carries high mortality. Radiation therapy for thoracic cancers is another treatment-related cause. Radiation-associated pericardial disease can appear acutely during treatment or emerge insidiously decades later, making long-term follow-up of cancer survivors important for catching cardiac complications early.

How Chronic Inflammation Reshapes the Heart

The common thread across all these causes is a cycle where inflammation triggers fibrosis and fibrosis perpetuates dysfunction. When heart muscle is injured, specialized cells called myofibroblasts activate and begin depositing extracellular matrix proteins, essentially laying down scar tissue.⁹ In a healthy response, this scarring is limited and reparative. In chronic carditis, the ongoing or recurrent inflammation keeps driving myofibroblast activity well beyond what repair requires.

As fibrosis progresses, the heart muscle stiffens. Regions of scar cannot conduct electrical signals normally, creating zones of blocked conduction that promote dangerous re-entrant arrhythmias. Fibrosis also disrupts the electrical coupling between heart muscle cells by reducing the function of key ion channels, increasing the risk of life-threatening ventricular arrhythmias like sustained ventricular tachycardia and ventricular fibrillation.¹⁰ Research in mouse models of viral myocarditis has identified specific molecular pathways, including one involving a protein called sST2 that activates fibroblasts while suppressing cellular senescence, as potential drivers of this cardiac scarring process. Blocking that pathway reduced fibrosis in the animal model.¹¹

Symptoms and Clinical Presentation

Chronic carditis is often insidious. Early on, patients may notice only mild fatigue or reduced exercise tolerance, symptoms easy to attribute to aging, deconditioning, or stress. As inflammation and fibrosis progress, more recognizable signs emerge. These vary depending on which layer of the heart is primarily affected:

• Chronic myocarditis: Progressive shortness of breath, palpitations, chest discomfort, and swelling in the legs or abdomen as the heart’s pumping ability declines.
• Chronic pericarditis: Recurrent sharp or pressure-like chest pain, often worse when lying down or breathing deeply, sometimes accompanied by a friction rub audible with a stethoscope.
• Chronic endocarditis: Fatigue, fevers that come and go, weight loss, new or worsening heart murmurs from valve damage, and occasionally embolic events like strokes or kidney damage from fragments of infected valve tissue breaking off.
• Constrictive pericarditis: A late consequence of chronic pericardial inflammation where the sac becomes thick and rigid, restricting the heart’s ability to fill. Patients develop progressive fluid retention, abdominal swelling, and exercise intolerance.

Constrictive pericarditis deserves extra attention because it mimics another condition, restrictive cardiomyopathy, closely enough that even seasoned cardiologists find it challenging to tell them apart. The two share overlapping hemodynamic features and echocardiographic findings, yet their management diverges sharply: constrictive pericarditis is surgically curable, while restrictive cardiomyopathy is managed medically.¹² Separating them often requires a combination of advanced imaging and invasive pressure measurements, and even then, roughly a quarter of patients could not be classified by hemodynamic criteria alone in one review.¹³

Diagnosing Chronic Carditis

The diagnosis usually starts with blood tests, an electrocardiogram, and echocardiography, but these tools can be inconclusive when inflammation is low-grade or patchy. Two more specialized approaches have become central to confirming chronic carditis.

Cardiac MRI uses tissue mapping techniques to detect edema and fibrosis. The revised Lake Louise criteria provide a framework for interpreting MRI findings in myocarditis. However, in patients whose carditis stems from an active autoimmune rheumatic disease, the combined criteria had a sensitivity of only about a third, meaning they missed two out of three cases, though specificity was perfect when both criteria were met.¹⁴ Using either criterion alone pushed sensitivity up to about two-thirds but introduced more false positives. This means cardiac MRI is helpful when positive, but a normal scan does not rule out chronic myocarditis, especially in autoimmune settings.

Endomyocardial biopsy remains the reference standard. A small tissue sample taken from inside the heart can reveal the type of inflammatory cells present, the degree of muscle cell damage and fibrosis, and whether specific features like granulomas or giant cells point to a particular cause. Adding molecular tests to the biopsy, such as PCR for viral genomes and immunohistochemistry for characterizing the inflammatory infiltrate, substantially increases diagnostic yield.¹⁵ A survey of pathologists found that about four in five use immunohistochemistry routinely or selectively, while about a third send samples for viral PCR.¹⁶ Identifying whether a virus is still present in the tissue is critical because it changes the treatment strategy entirely.

The search for reliable blood-based biomarkers continues. Standard markers like troponin and natriuretic peptides can signal heart damage and stress but are not specific to chronic inflammatory cardiomyopathy. Given the disease’s heterogeneity, researchers are working to identify cost-effective and prognostically useful biomarkers that could improve screening and guide treatment decisions without requiring invasive biopsy.¹⁷

Treatment Approaches

Treatment depends heavily on the underlying cause and the primary layer of the heart involved. There is no single “chronic carditis” therapy; instead, clinicians tailor the approach based on what the biopsy, imaging, and clinical picture reveal.

Recurrent Pericarditis

For chronic or recurrent pericarditis, colchicine has been the backbone of treatment. A meta-analysis found that colchicine roughly halved the risk of pericarditis recurrence compared with standard therapy. More recently, drugs that block interleukin-1, a key inflammatory signaling molecule, have shown even more dramatic results: anti-IL-1 agents reduced recurrence risk by about 88% in pooled data, with minimal variation between studies.¹⁸ Both anakinra and rilonacept have demonstrated efficacy in randomized trials, including in patients whose pericarditis was resistant to colchicine or who could not be weaned off corticosteroids.¹⁹ The success of these drugs has reinforced the understanding that the inflammasome pathway, the molecular machinery that processes IL-1, plays a central role in pericardial inflammation.²⁰

Virus-Negative Chronic Myocarditis

When biopsy confirms ongoing myocardial inflammation but no virus is detectable, immunosuppressive therapy can be effective. In a long-term follow-up study of patients with virus-negative chronic myocarditis or inflammatory cardiomyopathy, immunosuppression led to a significant improvement in heart pumping function that persisted over the long term. Biopsy-confirmed inflammatory cell counts dropped substantially after treatment.²¹ This is precisely why the biopsy distinction between virus-positive and virus-negative disease matters: suppressing the immune system in someone who still has an active viral infection in the heart could make things worse.

Standard Heart Failure Therapy

Regardless of the underlying cause, when chronic carditis has led to reduced heart function, standard heart failure medications form the foundation of care. ACE inhibitors or angiotensin receptor blockers, beta-blockers, and mineralocorticoid receptor antagonists help manage symptoms and slow the remodeling process. Diuretics relieve fluid overload. Newer agents like SGLT2 inhibitors have increasingly been incorporated as well. These medications treat the downstream consequences of chronic inflammation even while clinicians address the inflammation itself.

Surgical Options for Advanced Disease

When chronic pericarditis progresses to constrictive physiology, pericardiectomy, the surgical removal of the thickened pericardium, is generally indicated. This operation has a long track record. An analysis spanning eight decades at one institution found that short-term surgical mortality fell from about 14% in the earlier era to about 5% in more recent times.²² However, long-term survival has paradoxically worsened in the contemporary era, likely because surgeons are now operating on older patients with more comorbidities and more complex causes of constriction, including post-radiation cases.

Constrictive pericarditis frequently damages the tricuspid valve through chronic pressure overload. When significant tricuspid regurgitation is present, repairing or replacing the valve at the same time as pericardiectomy appears to be protective. A study found that adding tricuspid valve surgery did not increase operative mortality and was associated with better long-term outcomes, less residual regurgitation, and less right ventricular enlargement.²³

For chronic endocarditis that has destroyed a valve, valve repair or replacement is often necessary once the infection is controlled. In rheumatic heart disease, mitral valve surgery is one of the most performed cardiac operations globally.

The Arrhythmia Risk in Chronic Myocarditis

One of the most dangerous consequences of chronic myocarditis is the long-term risk of ventricular arrhythmias. Unlike the arrhythmias of the acute phase, which are driven by active inflammation and edema, arrhythmias in the chronic phase are generally scar-mediated, arising from re-entrant electrical circuits through fibrotic tissue.²⁴ This makes them unpredictable and potentially fatal even when the inflammation itself has burned out.

A study that followed patients with biopsy-proven myocarditis and implantable defibrillators for a median of about five and a half years found that nearly half experienced major ventricular arrhythmias requiring device intervention. The strongest predictors of needing a shock were having sustained ventricular tachycardia at the time of initial diagnosis and having larger areas of low electrical voltage, a surrogate for scar, on electroanatomical mapping of the heart’s inner surface. A scar burden exceeding about a tenth of the ventricular surface identified high-risk patients with both high sensitivity and high specificity.²⁵ These findings suggest that scar quantification, whether by MRI or invasive mapping, could help guide decisions about who should receive a defibrillator.

Chronic Carditis in Children

Children face some unique causes and trajectories of chronic carditis. Rheumatic heart disease hits hardest in school-age children in developing countries, but two conditions that surged during the COVID-19 pandemic highlighted pediatric cardiac inflammation in new ways.

Kawasaki disease, a febrile illness primarily affecting children under five, involves direct inflammatory cell infiltration around the coronary arteries and can lead to coronary artery aneurysms.²⁶ Multisystem inflammatory syndrome in children (MIS-C), which arose as a post-COVID complication, was initially thought to resemble Kawasaki disease closely. Both involve widespread inflammation, but MIS-C tends to cause more myocardial dysfunction through edema and stunning, while Kawasaki disease more aggressively damages coronary artery structure.²⁷

The good news from follow-up data is that the ventricular dysfunction seen in MIS-C tends to recover. In a multicenter study comparing the two conditions over one to three years, all cases of left ventricular dysfunction in MIS-C had resolved by the follow-up period. Only one MIS-C patient had a residual coronary aneurysm at follow-up, compared with about one in seven Kawasaki disease patients.²⁸ Kawasaki disease, when it does cause coronary aneurysms, can require lifelong surveillance and anticoagulation to prevent thrombosis and later coronary events.

Alcohol and Other Environmental Triggers

Not all chronic carditis begins with an infection or autoimmune process. Chronic heavy alcohol consumption can directly damage the heart muscle through the toxic effects of ethanol and its metabolites, a condition called alcoholic cardiomyopathy. The tissue damage closely resembles what you would see in chronic myocarditis, making it difficult to distinguish the two on biopsy alone.²⁹ Chronic alcohol abuse also raises blood pressure and suppresses the immune system, potentially increasing susceptibility to infections that compound the cardiac injury. Historically, contaminants in alcohol have caused their own outbreaks of heart disease, including cobalt-laced beer in Quebec and arsenic-tainted beer in Manchester. Today, the primary concern is the alcohol itself, and abstinence remains the single most effective intervention for halting progression when alcoholic cardiomyopathy is identified early.